Ananda S Bandyopadhyay Selected Research

Inactivated Poliovirus Vaccine (Salk Vaccine)

1/2021	Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
1/2021	Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials.
10/2018	Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review.
9/2017	The Immunogenicity of Fractional Intradermal Doses of the Inactivated Poliovirus Vaccine Is Associated With the Size of the Intradermal Fluid Bleb.
1/2017	Inactivated polio vaccines from three different manufacturers have equivalent safety and immunogenicity when given as 1 or 2 additional doses after bivalent OPV: Results from a randomized controlled trial in Latin America.
7/2016	Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
1/2016	Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
11/2015	Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ananda S Bandyopadhyay Research Topics

Disease

31	Poliomyelitis (Polio) 06/2022 - 01/2015
3	Infections 01/2019 - 12/2016
2	acute flaccid myelitis 06/2022 - 01/2018
2	Paralysis (Palsy) 02/2022 - 01/2022
1	COVID-19 09/2021
1	Hypersensitivity (Allergy) 01/2021
1	Blister (Bulla) 09/2017
1	Rubella (German Measles) 01/2016
1	Yellow Fever 01/2016
1	Measles 01/2016
1	Intussusception 11/2015

Drug/Important Bio-Agent (IBA)

30	VaccinesIBA 06/2022 - 01/2015
11	Oral Poliovirus Vaccine (Sabin Vaccine)IBA 01/2022 - 11/2015
8	Inactivated Poliovirus Vaccine (Salk Vaccine)FDA Link 01/2021 - 11/2015
3	Immunoglobulin A (IgA)IBA 01/2019 - 01/2018
2	Poliovirus VaccinesIBA 01/2022 - 01/2021
2	Neutralizing AntibodiesIBA 01/2021 - 12/2017
2	hydroxide ionIBA 01/2020 - 01/2017
2	AluminumIBA 01/2020 - 01/2017
2	Combined VaccinesIBA 10/2018 - 01/2016
2	AntibodiesIBA 10/2018 - 12/2016
1	5' Untranslated Regions (5' UTR)IBA 02/2022
1	dimethylaminonaphthalene- 5- sulfonaminoethylmethylamine (DDNS)IBA 01/2022
1	pocapavirIBA 01/2019
1	Antiviral Agents (Antivirals)IBA 01/2019
1	AntigensIBA 01/2018
1	Viral ProteinsIBA 01/2018
1	Yellow Fever Vaccine (Vaccine, Yellow Fever)FDA Link 01/2016